• Mon, Jan. 16, 5:43 AM
    • President-elect Donald Trump has pledged to provide "insurance to everybody" under his plan to replace Obamacare, The Washington Post reports.
    • "It's very much formulated down to the final strokes. We haven't put it in quite yet but we're going to be doing it soon," he said. People covered under the law "can expect to have great health care. It will be in a much simplified form. Much less expensive and much better."
    • Trump also promised to force pharmaceutical companies to directly negotiate drug prices with the government for Medicare and Medicaid, stating "they're politically protected, but not anymore."
    • Related tickers: UNH, AET, ANTM, CI, HUM, WCG, CNC, MOH, GTS, HQY, HCA, THC, UHS, LPNT, CYH, HCP, SEM
    Mon, Jan. 16, 5:43 AM | 246 Comments
  • Thu, Jan. 12, 2:18 AM
    • After debating seven hours through the night, the Senate narrowly passed a budget resolution early Thursday, clearing the first major hurdle in the GOP effort to repeal Obamacare.
    • House leaders plan to take it up tomorrow amid pressure from President-elect Donald Trump; he said on Wednesday that the repeal and replacement should happen "essentially simultaneously."
    • Related tickers: UNH, AET, ANTM, CI, HUM, WCG, CNC, MOH, GTS, HQY, HCA, THC, UHS, LPNT, CYH, HCP,SEM
    Thu, Jan. 12, 2:18 AM | 119 Comments
  • Dec. 29, 2016, 3:51 AM
    • Upping the ante on his calls to reform the veterans health care system, President-elect Donald Trump convened a meeting on Wednesday to explore additional ways to enable veterans to obtain private medical treatment.
    • "We think we have to have kind of a... public-private option," a senior transition official told reporters. "It's one of the options on the table."
    • Related tickers: UNH, AET, ANTM, CI, HUM, WCG, CNC, MOH, GTS, HQY
    Dec. 29, 2016, 3:51 AM | 16 Comments
  • Dec. 22, 2016, 3:59 AM
    • It's a record, but will it be Trumped?
    • Federal health officials are touting a record 6.4M customer sign-ups on HealthCare.gov so far this open enrollment season (not including re-enrollments and individual markets), topping last year's pace by 400K customers.
    • Trump has said he wants to replace Obamacare after its repeal with something "better," but it's still not clear what such a replacement would look like.
    • Related tickers: UNH, AET, ANTM, CI, HUM, WCG, CNC, MOH, GTS, HQY
    Dec. 22, 2016, 3:59 AM | 11 Comments
  • Dec. 21, 2016, 1:14 PM
    • JPMorgan initiates coverage on Centene (CNC +3.3%) with an Overweight rating and $75 (28% upside) price target.
    • C.L. King initiates coverage on OraSure Technologies (OSUR +1.8%) with a Buy rating and $11 (22% upside) price target.
    Dec. 21, 2016, 1:14 PM | 1 Comment
  • Dec. 8, 2016, 7:30 AM
    • Philip van Doorn and team at Marketwatch put together a list of 18 S&P 500 names with consensus sell-side price targets at least 30% above the current price.
    • Ten of the 18 stocks are in healthcare, which has been roughed up by a combination of Obamacare, Clinton's talk about drug pricing (back when all thought she would be the next POTUS), and now Trump joining in the bashing.
    • The list (in order of possible upside): Mallinckrodt PLC (NYSE:MNK) - 56% potential upside, Endo International PLC (NASDAQ:ENDP) - 52% upside, Hanesbrands (NYSE:HBI) - 45% upside, Edwards Lifesciences (NYSE:EW) - 44% upside, Mylan (NASDAQ:MYL) - 42% upside, Allergan (NYSE:AGN) - 39% upside, Alexion (NASDAQ:ALXN) - 37% upside, Activision Blizzard (NASDAQ:ATVI) - 35% upside, Salesforce.com (NYSE:CRM) 34% upside, NRG Energy (NYSE:NRG) - 34% upside, Centene (NYSE:CNC) 34% upside, Gilead (NASDAQ:GILD) 33% upside, Facebook (NASDAQ:FB) 32% upside, Boston Scientific (NYSE:BSX) - 32% upside, Pitney owes (NYSE:PBI) - 32% upside, Molson Coors (NYSE:TAP) - 30% upside, Newell Brands (NYSE:NWL) - 30% upside, Zimmer Bioment (NYSE:ZBH) - 30% upside.
    Dec. 8, 2016, 7:30 AM | 33 Comments
  • Dec. 6, 2016, 8:03 AM
    • Tenet Healthcare (NYSE:THC) and Centene (NYSE:CNC) sign a new three-year agreement providing Centene and Health Net members in-network access to Tenet's hospitals, outpatient centers and employed physicians in 18 states. The new contract integrates all of Centene's and Health Net's insurance products into a single agreement following Centene's acquisition of Health Net earlier this year.
    • The contract will go into effect January 1.
    Dec. 6, 2016, 8:03 AM
  • Nov. 9, 2016, 12:42 PM
    Nov. 9, 2016, 12:42 PM
  • Nov. 9, 2016, 11:06 AM
    Nov. 9, 2016, 11:06 AM | 5 Comments
  • Nov. 9, 2016, 3:03 AM
    • Healthcare stocks, the weakest sector this year, may become winners, as Obamacare reforms are set to be "repealed and replaced" and major legislation Clinton proposed is unlikely to be imposed on drugmakers.
    • While Trump hasn't set out a comprehensive alternative to the Affordable Care Act (which may see 22M Americans lose current coverage), he said he'll encourage competition between markets in different states.
    • Insurance stocks: UNH, AET, ANTM, CI, HUM, WCG, CNC, MOH, GTS, HQY
    • Drugmakers premarket: MYL +5.8%, NVS +3.4%, SNY +2.9%, AZN +2.4%, GSK +1.9%, PFE +1.8%, CELG +1%, ABBV, MRK, BMY, LLY, JNJ, ABT, ACET, ZTS, BIIB, REGN
    • #Election2016
    Nov. 9, 2016, 3:03 AM | 15 Comments
  • Oct. 27, 2016, 3:41 AM
    • Not only are Obamacare premiums on the rise for 2017, deductibles will also be getting more expensive, according to an analysis by insurance comparison site HealthPocket.
    • Deductibles for individuals enrolled in the lowest-priced Obamacare health plans will average more than $6,000 next year, the first time that threshold has been cracked in the three years that Affordable Care Act marketplaces have been in business. Families enrolled in the bronze plans will average deductibles of $12,393.
    • Previously: Obamacare rates up 25% in 2017 (Oct. 25 2016)
    • Related tickers: UNH, AET, ANTM, CI, HUM, WCG, CNC, MOH, GTS, HQY
    Oct. 27, 2016, 3:41 AM | 42 Comments
  • Oct. 25, 2016, 8:30 AM
    • Centene (NYSE:CNC) Q3 results ($M): Total Revenues: 10,846 (+86.3%); Premium: 9,625 (+93.2%); Service: 590 (+22.9%); Premium Tax and Health Insurer Fee: 631 (+76.3%);
    • Net Income: 145 (+55.9%); EPS: 0.84 (+12.0%); Non-GAAP EPS: 1.11 (+27.6%); CF Ops: 255 (9 mo.): 255 (-44.2%);
    • Operating Expenses: 10,504 (+86.3%); Medical Costs: 8,376 (+88.9%); Health Benefits Ratio: 87.0% (-2.2%).
    • 2016 Guidance: Total Revenues: $39.4B - 40.0B (unch); EPS: $2.73 - 2.83 from $2.65 - 3.00; Non-GAAP EPS: 4.28 - 4.38 from $4.20 - 4.55.
    • Q4 Guidance: EPS: $0.83 - 0.93; Non-GAAP EPS: $1.05 - 1.15.
    Oct. 25, 2016, 8:30 AM
  • Oct. 25, 2016, 6:06 AM
    • Centene (NYSE:CNC): Q3 EPS of $1.16 in-line.
    • Revenue of $10.85B (+86.4% Y/Y) misses by $110M.
    • Shares +0.08% PM.
    • Press Release
    Oct. 25, 2016, 6:06 AM | 1 Comment
  • Oct. 25, 2016, 2:22 AM
    • The average premium for benchmark 2017 Obamacare insurance plans sold on Healthcare.gov will jump 25% to $302 compared to this year, the biggest increase since the insurance first went on sale in 2013.
    • Seeking to downplay the cost hikes, the administration said that including subsidies 77% of people would be able to find insurance plans with monthly premiums below $100, however, one in five consumers will only have one insurer from which to choose coverage.
    • Related tickers: UNH, AET, ANTM, CI, HUM, WCG, CNC, MOH, GTS, HQY
    Oct. 25, 2016, 2:22 AM | 43 Comments
  • Oct. 24, 2016, 5:30 PM
    Oct. 24, 2016, 5:30 PM | 28 Comments
  • Sep. 9, 2016, 9:59 AM
    • Eli Lilly (NYSE:LLY) upgraded to Overweight from Neutral by JPMorgan. Price target raised to $95 (20% upside) from $92.
    • Ligand Pharmaceuticals (NASDAQ:LGND) upgraded to Hold from Sell by Deutsche Bank. Price target raised to $110 (2% downside risk) from $105.
    • Gilead Sciences (NASDAQ:GILD) upgraded to Buy from Hold by Jefferies. Price target raised to $91 (16% upside). Morgan Stanley rates it Hold with a price target of $100 (27% upside).
    • Teva Pharmaceutical Industries (NASDAQ:TEVA) upgraded to Outperform from Market Perform with a $66 price target by Oppenheimer.
    • Novo Nordisk (NYSE:NVO) downgraded to Neutral from Overweight by JPMorgan.
    • AbbVie (NYSE:ABBV) downgraded to Neutral from Overweight with a $73 (14% upside) price target by JPMorgan.
    • Cepheid (NASDAQ:CPHD) downgraded to Neutral from Buy by BTIG Research.
    • Tonix Pharmaceuticals (NASDAQ:TNXP) downgraded to Neutral from Buy by Roth Capital.
    • Momenta Pharmaceuticals (NASDAQ:MNTA) downgraded to Sell from Hold with a $6 (48% downside risk) price target by Maxim Group.
    • Biogen (NASDAQ:BIIB) downgraded to Hold from Buy with a $323 (7% upside) price target by Jefferies.
    • Centene (NYSE:CNC) downgraded to Market Perform from Outperform with an $80 (19% upside) price target by Leerink Swann. Wedbush rates it Outperform with an $85 (26% upside) price target.
    Sep. 9, 2016, 9:59 AM | 12 Comments